Last reviewed · How we verify
NCT07441863
Structured Pulmonary Physiotherapy After Lung Cancer Surgery by Age Group
NA trial testing Structured Postoperative Pulmonary Physiotherapy Program in Lung Cancer in 60 participants. Completed in 2 March 2026.
2 March 2026
Quick facts
| Lead sponsor | Bezmialem Vakif University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 June 2025 |
| Primary completion | 2 March 2026 |
| Estimated completion | 2 March 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Structured Postoperative Pulmonary Physiotherapy Program
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Postoperative Pulmonary Complications — all drugs for Postoperative Pulmonary Complications →
Sponsor
Bezmialem Vakif University
Who can join
Adults 45 to 90, any sex, with Lung Cancer or Postoperative Pulmonary Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, single-arm interventional study aims to evaluate the effectiveness of a structured postoperative pulmonary physiotherapy program delivered by the research team in patients undergoing lung cancer surgery. The intervention consists of chest physiotherapy, bronchial hygiene techniques, early mobilization, and postural exercises applied under physiotherapist supervision during the postoperative hospital stay. The primary outcome is length of hospital stay. Secondary outcomes include blood pressure, heart rate, oxygen saturation, fatigue, and dyspnea levels. Clinical outcomes will be analyzed according to age groups (45-59 years and 60-90 years) to determine potential age-related differences in response to the intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07441863
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Bezmialem Vakif University trials
Trials by the same sponsor.
- NCT07369297 — PULP SENSIBILITY AND MASSETER INHIBITORY REFLEX IN DIABETIC POLYNEUROPATHY · not yet recruiting
- NCT07433595 — Association Between Child and Parental Stress and Bruxism in Children Aged 8-11 Years · not yet recruiting
- NCT07443111 — Comparison of Virtual Reality-Based and Routine Preoperative Education on Surgical Anxiety and Salivary Cortisol · NA · not yet recruiting
- NCT07421349 — Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy P · not yet recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07441863 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bezmialem Vakif University
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07441863.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing